X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Neogenix Oncology was organized in 2004 when Dr. Ariel Hollinswhead, professor of medicine and head of the George Washington University Cancer Research Laboratory, assigned her research on developing therapeutic and diagnostic products to treat pancreatic, colon, lung, prostate and colorectal cancers to the company. Its efforts focused primarily on the development of therapeutic monoclonal antibodies targeted against pancreatic and colorectal cancer. To fund itself through the start-up and developmental stages it relied on the sale of its common stock to third parties. And this is where our tale of woe begins.1

This content has been archived. It is available exclusively through our partner LexisNexis®.

To view this content, please continue to Lexis Advance®.

Not a Lexis Advance® Subscriber? Subscribe Now

Why am I seeing this?

LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.

ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.

For questions call 1-877-256-2472 or contact us at customercare@alm.com

 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.